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Chronic Obstructive Pulmonary Disease (COPD) is a dis-
order of the respiratory system characterized by progres-
sive and only partially reversible airflow obstruction, due
to a varying combination of large (bronchitis) and small
airways (small airway disease) damage, and lung parenchy-
mal and vascular destruction [1]. We prefer the term
obstruction to airflow limitation because the latter is a
physiologic event which occurs also in normals at high
levels of ventilation, for example during exercise. The cor-
rect definition should be “excessive airflow limitation” to
indicate that the reduction in airflow occurs at lower level
of ventilation than in normal condition. The diagnostic
procedure for COPD starts from the recognition of risk
factors (cigarette smoking “in primis”, but also outdoor
and indoor air pollution [2]) and the presence of symp-
toms such as chronic cough and phlegm and reduced
exercise tolerance. The lifestyle is important for the reveal
of symptoms: dyspnea occurs later in a sedentary person
than in an active individual.
The objective demonstration of airflow obstruction by
spirometry is mandatory to establish the diagnosis. A
post-bronchodilator FEV1/FVC < 0.70 is considered suffi-
cient to define airflow obstruction and to confirm the
diagnosis [3,4]. FVC = forced vital capacity; FEV1 = forced
expiratory volume in the 1st second; VC = (slow) vital
capacity. Some Guidelines requires that FEV1/FVC < 0.70
[5] should be associated with a FEV1 < 80% of the pre-
dicted value [1,6]. Many Authors [7], however, and some
official documents [8,9] do not accept the fixed “cut-off”
and indicate the FEV1/VC < lln (lower limit of normality)
as a more correct documentation of airflow obstruction.
The debate is still ongoing [10]. However, it seems to be a
general agreement to use the value of FEV1%predicted to
stage the severity of the disease. Neverthless, it would be
more appropriate to accept the use of that measurement
for staging only the severity of airflow obstruction, not the
whole disease state. In fact COPD is a heterogeneous
disorder with diverse pathophysiological manifestations at
the level of the respiratory system as well as at systemic
level with complications and comorbidities. Not surpris-
ingly, the FEV1 is rather insufficient to assess the status
and progress of the disease as well as the effects of thera-
pies. Although very helpful and valuable, the FEV1 has
several limitations which should be taken into account
when interpreting its value and changes.
First of all it should be remembered that FEV1 results
from two undisclosed determinants, i.e. the caliber of the
large airways and the lung elastic recoil. The latter is
poorly sensitive to treatments whereas the former can be
improved by either pharmacological [11] and/or non phar-
macological [12] treatments. Therefore, the individual
response to therapies depends upon which determinant
drives the FEV1 reduction more. Furthermore, the FEV1
is rather insensitive to small airway disease, which is an
important pathology of COPD [13] and may be extensively
present when spirometry is still within the normal range
[14].
Respiratory pathophysiology
Airflow obstruction is the hallmark of COPD. However,
the pathophysiology of COPD is intricate. In fact, it
encompasses also pulmonary hyperinflation and nonuni-
form distribution of ventilation [15]. Lung hyperinflation
has two components:
￿ static, i.e. the increase in functional residual capacity
(FRC) due to the loss of lung elastic recoil because of
destruction of lung parenchyma, and
￿ dynamic, i.e. the position of the end-expiratory lung
volume above the relaxed volume of the respiratory sys-
tem, (for example during exercise or exacerbations).
Hyperinflation may be a predictor of mortality when
expressed as IC/TLC%. IC = inspiratory capacity; TLC =
total lung capacity [16].
Small airways disease and parenchymal destruction
result in maldistribution of ventilation leading to ventila-
tion-perfusion mismatching and eventually causing lung
failure and hypoxemia. On the other hand, pulmonary
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the respiratory muscles eventually leading to ventilatory
pump failure, and hypercapnia [17]. None of these patho-
p h y s i o l o g i ce v e n t si sc o r r e l a t e dt ot h ec h a n g e si nF E V 1 ,
which, at the same time, is poorly related to exercise
capacity and symptoms intensity. However, this elaborate
respiratory pathophysiology is not the end of the COPD
heterogeneous picture. Systemic effects must be taken
into account to understand correctly the real severity of
the disease in different patients.
Systemic effects
The skeletal muscles are affected unfavourably by COPD.
Exercise intolerance worsens with the progression of the
disease [18]. Obviously, the first individual reaction is to
prevent that “unpleasant sensation of difficult breathing”
(i.e. dyspnea) by limiting exercise and life activity. Under
those circumstances, skeletal muscles undergo progres-
sive deconditioning and the vicious circle is elicited: dys-
pnea - activity limitation - muscle deconditioning -
dyspnea [19]. Often, malnutrition can aggravate the loss
of skeletal muscles force.
Chronic cor pulmonale is a well known complication of
advanced COPD. However, a recent large, population
based study has shown that impaired left ventricular fill-
ing, reduced stroke volume, and lower cardiac output
were linearly related to the extent of emphysema at the
CT scanning and to the severity of spirometric airflow
obstruction [20]. However, in that study, the FEV1/FVC
ratio was, on average, above 0.64, a value only slightly
below the 0.70 limit accepted as normal. Therefore, the
cardiovascular system in COPD patients is challenged not
only by the common risk factor, i.e. cigarette smoking, but
also by emphysema at earlier stages than traditionally
thought.
Exacerbations
T h ea s s e s s m e n to fC O P Ds e v e r i t yc a n n o ti g n o r et h e
occurrence of exacerbations, which are a prominent fea-
t u r eo ft h en a t u r a lh i s t o r yo fC O P D .T h e yi n f l u e n c et h e
progression of the disease and are a major cause of mor-
bidity and mortality, and socio-economic cost [21]. Many
data support the conclusion that exacerbations are more
frequent and more severe in patients with advanced air-
flow obstruction. However, the ECLIPSE study [22]
found that although exacerbations become more frequent
and more severe as COPD progresses, the rate at which
they occur appears to reflect an independent susceptibil-
ity phenotype.
Therefore, it is not surprising that a single variable, such
as for example the FEV1, cannot capture the heterogeneity
of COPD, both pulmonary and systemic [23]. In addition,
the individual patient with COPD is often affected by
comorbidities, because other diseases are common at the
age when COPD becomes clinically revealed, for example
systemic arterial hypertension, diabetes, obesity etc.
In summary, the modern approach to the COPD patient
goes beyond the necessary demonstration of airflow
obstruction and the understanding of the complex pul-
monary pathophysiology to embody the systemic effects
and comorbidities [24,25]. This view encouraged the
development of multidimensional indices to provide physi-
cian with some robust instrument to ascertain the status
and progress of the disease as well as to guide therapy in
the individual patient.
In this issue of Respiratory Research, Wouter D. van
Dijk and colleagues [26] provide a systematic review of 15
multidimansional indices selected in 13 studies from >
7000 articles screened in the Pubmed and Embase litera-
ture database. This laudable effort concluded however that
“although the prognostic performance of the indices has
been validated, they all lack sufficient evidence on imple-
mentation”. Obviously it is not an Authors’ fault. It is the
discrepancy between the complexity of the disease and the
need to find something measurable to be helpful, clear,
and easy for its use in the clinical practice. The population
based prediction might be improved by some indices
which may however lack feasibility in the real life of the
individual patient-doctor relationship. A good example of
this dilemma is the FEV1 decline. Since the classic study
by Fletcher and colleagues [27,28] it is widely accepted
that the rate of decline of the FEV1 might be regarded as a
marker of the progression of COPD related to important
outcomes such as disability and death [29]. However, the
starting point of the FEV1 might be influenced by the
impact of factors, not related to COPD, in early life or
even in the pre-birth period on adult lung function.
Furthermore, the rate of decline of the FEV1 cannot be
used in the clinical practice because it would require a
minimum of observation for two years, with at least three-
four measurements of FEV1 per year: the first year to
compute the baseline decay and the second year, after the
start of the treatment, to document the slowdown of the
decay. Rather impractical!
Great expectations are generated by molecular and
genomic research [30]. The result of gene-environment
interactions determines the clinical presentation of the
disease: the clinical phenotype. It might be that a better
identification of COPD phenotypes would lead to identi-
fication of specific indices customized to a particular
phenotype. The traditional classification of COPD pheno-
types pertains to the classic “blue-bloater” and “pink-
puffer” pictures [31]. However, it has been suggested
already several years ago that many patients fall into
neither group and that those descriptive terms are not
clearly related to specific functional or pathologic fea-
tures. Therefore its use is not encouraged [8]. By con-
trast, other phenotypes have been recommended. The
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notype [32-34], which could be further classified into
three “clinical phenotypes” termed bacteria-associeted,
virus-associeted and eosinophil-associeted [34]. This has
meaningful implication for clinical practice for both the
therapeutic approach [21,35] and the choice of the multi-
dimensional index, which should include the exacerba-
tion occurrence. For example, the DOSE [36] might
apply better to this phenotype rather than to the general
COPD population.
Currently, COPD and asthma are differentiated, but we
all accept that some areas of overlap exist. Their recogni-
tion may influence the therapeutic decision, for example
the use of inhaled corticosteroids [3,37,38]. Lung function
tests such as assessment of airway reactivity [39] or mea-
surement of single-breath carbon monoxide transfer factor
(TL,CO) [8,40] could be particularly useful to monitor this
segment of patients. In some cases the detection of eosino-
philic sputum might be useful [41].
The analysis of data from large, longitudinal studies has
brought to attention the fact that FEV1 decline is not uni-
form throughout the progression of the disease but it may
be larger at early stage, when there is more to lose, and
smaller in the advanced stage when it remains little to be
lost [42,43]. A subgroup of so called “rapid decliner”
[44,45] might reflect another phenotype of the disease. In
this subgroup, or clinical phenotype, repeated measure-
ment of FEV1 could be much more valuable than in other
sub-groups.
In conclusion, as the picture of COPD becomes more
complex and the results from large studies generate the
need of further research, it is clear the close link between
the definition of clinical phenotypes and the validation of
either single or multidimensional indices. The line of
search marker, either biological or physiological, for one
COPD has come to its end. The definition of multiple
clinical phenotype crosses repeatedly and systematically
the evolution of indices and markers. From the cross-
matching of multiple phenotypes and multidimensional
indices we cannot expect the birth of a single variable to
assess the heterogeneous COPD, but multiple variables
for different COPDs: “e pluribus plurima”.
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